Latest news with #Elevance
Malaysian Reserve
15 hours ago
- Business
- Malaysian Reserve
Faruqi & Faruqi Reminds Elevance Health Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 11, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elevance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elevance between April 18, 2024 and October 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 20, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Elevance Health, Inc. ('Elevance' or the 'Company') (NYSE: ELV) and reminds investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While Defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in the Company's guidance for the year. The truth began to emerge on July 17, 2024, when the Company revealed that it was now 'expecting second-half utilization to increase in Medicaid.' In response to this disclosure, the price of Elevance common stock declined by $32.21 per share, or 5.8%. However, Defendants continued to make false, reassuring statements to investors concerning the extent of the cost increase and how that was accounted for in the Company's full year guidance. The truth was further revealed on October 17, 2024, when Elevance announced its financial results for the third quarter of 2024, revealing that the Company had missed consensus earnings per share ('EPS') expectations for the quarter by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' Elevance further revealed that it was lowering EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, as it expected these Medicaid issues to continue. These disclosures caused the price of Elevance common stock to decline by another $52.61 per share, or 10.6%. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Elevance's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Elevance Health class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Malaysian Reserve
04-06-2025
- Business
- Malaysian Reserve
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elevance
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Elevance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Elevance between April 18, 2024 and October 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 4, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Elevance Health, Inc. ('Elevance' or the 'Company') (NYSE: ELV) and reminds investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While Defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in the Company's guidance for the year. The truth began to emerge on July 17, 2024, when the Company revealed that it was now 'expecting second-half utilization to increase in Medicaid.' In response to this disclosure, the price of Elevance common stock declined by $32.21 per share, or 5.8%. However, Defendants continued to make false, reassuring statements to investors concerning the extent of the cost increase and how that was accounted for in the Company's full year guidance. The truth was further revealed on October 17, 2024, when Elevance announced its financial results for the third quarter of 2024, revealing that the Company had missed consensus earnings per share ('EPS') expectations for the quarter by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' Elevance further revealed that it was lowering EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, as it expected these Medicaid issues to continue. T These disclosures caused the price of Elevance common stock to decline by another $52.61 per share, or 10.6%. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Elevance's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Elevance Health class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Associated Press
04-06-2025
- Business
- Associated Press
ELV LAWSUIT NOTICE: Lose Money on Elevance Health, Inc.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NYSE:ELV)
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092. Why was Elevance Sued for Securities Fraud? Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility. During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid. As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance's Medicaid members. What's more, the shift occurred to a degree that was not reflected in Elevance's rate negotiations or in its financial guidance for 2024. The Stock Declines as the Truth is Revealed On July 17, 2024, Elevance stated that it was now 'expecting second-half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population.' On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024. Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ('EPS') expectations by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024. Click here if you suffered losses: What Can You Do? If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Irish Times
29-05-2025
- Business
- Irish Times
Tariff threat a budget headache for Minister and investment pays for Trinity College
Paschal Donohoe is not looking forward to the budget process if his evidence to an Oireachtas committee is anything to go by. He said making 'confident predictions' about the impact on the Irish economy of a breakdown in trade relations between the US and Europe, is without precedent, and that forecasting short-term scenarios – key to the budget arithmetic – has never been more difficult. Ian Curran reports. Trinity College recorded a surplus in excess of €50 million last year, according to accounts just published but still described their finances as 'finely balanced'. Hugh Dooley finds out why. US health insurance giant Elevance opened an Irish business less than four years ago and rebranded with fanfare in Thomond Park just over two years ago. Now it is packing up, cutting more than 300 staff at its Limerick operation loose. Legendary Apple designer Jony Ive and artificial intelligence pioneer Sam Altman are promising to create a device that will take artificial intelligence firmly into the real world, reimagining what it means to use a computer. They're not the first to make such promises and Ciara O'Brien suggests it is not yet time to turn your back on the current generation of technology. READ MORE Meta's chief privacy officer warns that Europe risks becoming the 'museum of the world'. Her particular bone of contention is the EU's wariness of Meta plans to start using the public posts, comments and other data of EU users to train its AI models. She tells Ciara it is just an attempt 'by a vocal minority of activist groups to delay AI innovation in the EU and that ultimately harms consumers and businesses who can benefit from these technologies'. The Irish Hotels Federation says it is joining a Europe-wide legal action against over what they say are inflated commission rates they were forced to pay over 20 years. Conor Pope has the details. Ireland's largest business lobby group, Ibec, says skills gaps and mismatches in the Irish workforce are 'eroding the competitiveness of Irish industry' though it's somewhat short on details, writes Hugh Dooley. Meanwhile, the Convenience Stores & Newsagents Association has secured High Court sanction to proceed with a judicial review of what it says are 'punitive' fees to sell tobacco and nicotine products from next year. Corner stores currently paying €50 a year for the privilege will face bills of €1,800 under the new regime. Hugh has the details. Marketing and advertising budgets are often the first casualties during times of economic stress. So a new report that foresees stagnating client spending this year might be cause for concern. Ian Curran reports. Eoin Burke-Kennedy assesses a KPMG report that says Dublin needs a €70 billion investment in housing, transport, water and energy over 15 years if it is to catch up on years of underinvestment that has seen the city outgrow its infrastructure. When Covid disrupted retail, fashion designer Aideen Bodkin turned her attention to the thorny question of ensuring clothes bought online actually fit. Now she has developed an AI-powered tool for fashion retailers that matches customer measurements to a brand's sizing to ensure the perfect fit first time. 'I spent over 20 years in high-end ladies fashion and, in recent years, I've watched in horror as fast fashion and overconsumption have become normalised. Over 50 per cent of global online garment returns stem from incorrect fit and this fuelled my commitment to create an innovative sizing solution,' Bodkin says. Finally, on our Inside Business podcast , Lisa Brankin, chairman and managing director of Ford UK & Ireland, joins host Cliff Taylor to discuss the challenges of going electric, her plans for the company's future, and the launch of Ford Power Promise across its range of electric cars in Ireland. If you'd like to read more about the issues that affect your finances try signing up to On the Money , the weekly newsletter from our personal finance team, which will be issued every Friday to Irish Times subscribers.
Yahoo
28-05-2025
- Business
- Yahoo
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
Elevance Health, Inc. ELV, a leading U.S. health benefits provider, appears to be trading at a discount. Its forward 12-month P/E ratio stands at just 10.35X, significantly below its five-year median of 13.46X and the industry average of 13.86X. Compared to peers, UnitedHealth Group Incorporated UNH and Humana Inc. HUM, which trade at 12.06X and 14.73X, respectively, ELV looks attractively valued. It currently holds a Zacks Value Score of A, highlighting strong valuation fundamentals. But is this discount a sign of hidden opportunity, or a red flag? Let's explore the drivers behind Elevance's valuation and its long-term outlook. Image Source: Zacks Investment Research Headquartered in Indianapolis, Elevance is well-positioned for sustained growth, underpinned by strategic initiatives across its commercial and government segments. Elevance continues to see steady growth in its commercial segment. In 2024, risk-based and fee-based commercial memberships grew 4.6% and 1% year-over-year. Its Individual Commercial business is especially strong, reporting a 14.2% surge in the first quarter of 2025 alone. By exiting underperforming markets, Elevance has streamlined its government business, improving overall efficiency. It also has room to expand its Medicare Advantage footprint in underpenetrated states, which could unlock future and dental memberships continue to witness growing momentum. With a Return on Invested Capital of 9.94%, far above the industry average of 5.79%, Elevance demonstrates superior capital deployment. Its $84.1 billion market cap gives it the scale to pursue strategic acquisitions and reallocations toward higher-margin businesses. ELV remains committed to returning capital to shareholders. In the first quarter of 2025 alone, it repurchased $880 million worth of shares and had $8.4 billion remaining under its buyback authorization. Its dividend yield of 1.82% also exceeds the industry average of 1.40%. Despite headwinds in the broader market, ELV shares have gained 1.9% year to date, outperforming both the industry and the S&P 500. In contrast, UnitedHealth and Humana have posted declines, reflecting broader sectoral pressure. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Elevance's 2025 and 2026 EPS implies a 4.2% and 13.8% uptick, respectively, on a year-over-year basis. The estimates remained stable over the past week. Moreover, the consensus mark for 2025 and 2026 revenues suggests an 11.2% and 7.1% increase, respectively. The company beat earnings estimates in three of the past four quarters and missed once. This is depicted in the figure below. Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote Despite its strengths, Elevance faces some notable challenges. A key concern is the decline in Medicaid and Medicare Supplement membership, leading to both overall membership losses and reduced revenues. A drop in government funding could put additional pressure on profitability. Increasing medical costs pose a massive challenge as industry players continue to struggle with rising utilization and squeezing margins. The company's benefit expense ratio, measuring the portion of premiums spent on claims, has been increasing, rising from 87% in 2023 to 88.5% in 2024. Our estimate suggests it could reach 88.7% in 2025, signaling further pressure on earnings. Policy shifts such as the Most Favored Nation drug pricing model introduced by the Trump administration have rattled the Pharmacy Benefit Management (PBM) industry. With major PBM exposure, Elevance — like UnitedHealth, CVS and others — faces uncertainty in this space. Elevance Health offers an appealing valuation and demonstrates strong fundamentals in its commercial business, capital efficiency and shareholder returns. However, ongoing pressures from rising medical costs, government program headwinds, and regulatory uncertainties temper the bullish case. With a Zacks Rank #3 (Hold), the stock reflects a balanced risk-reward profile. It may not be a screaming buy at the moment, but it remains a solid name to watch, especially for long-term investors seeking stability, value and consistent execution in the healthcare space. Patience may be warranted until clearer signals on regulatory outcomes emerge. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
